{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:05:53Z","timestamp":1791558353361,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ygyno.2025.11.022","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T20:18:45Z","timestamp":1764965925000},"page":"202-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)"],"prefix":"10.1016","volume":"204","author":[{"given":"Mark S.","family":"Shahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raina","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Parthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakirthi","family":"Yerram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Kesner-Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia Cristina","family":"Tudor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Dobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Jubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.11.022_bb0005","author":"International Agency for Research on Cancer"},{"key":"10.1016\/j.ygyno.2025.11.022_bb0010","author":"National Cancer Institute"},{"key":"10.1016\/j.ygyno.2025.11.022_bb0015","author":"National Comprehensive Cancer Network"},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.022_bb0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.23.01771","article-title":"Treatment approaches for platinum-resistant ovarian cancer","volume":"42","author":"Laurent","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2025.11.022_bb0025","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.022_bb0030","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/medicina59030544","article-title":"Ovarian cancer\u2014insights into platinum resistance and overcoming it","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina"},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.022_bb0035","first-page":"202","article-title":"Update on strategies for platinum-resistant ovarian cancer","volume":"21","author":"Pothuri","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.022_bb0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.22.02915","article-title":"Ofranergene obadenovec (Ofra-Vec, VB-111) with weekly paclitaxel for platinum-resistant ovarian cancer: randomized controlled phase III trial (OVAL study\/GOG 3018)","volume":"42","author":"Arend","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.11.022_bb0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamaoncol.2022.7966","article-title":"Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial","volume":"9","author":"Banerjee","year":"2023","journal-title":"JAMA Oncol."},{"issue":"17 suppl","key":"10.1016\/j.ygyno.2025.11.022_bb0050","article-title":"AXLerate-OC\/GOG-3059\/ENGOT OV-66: results of a phase 3, randomized, double-blind, placebo\/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer","volume":"42","author":"Fuh","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2025.11.022_bb0055","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.022_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115306","article-title":"Tumor treating fields therapy in platinum-resistant ovarian cancer: results of the ENGOT-ov50\/GOG-3029\/INNOVATE-3 pivotal phase 3 randomized study","volume":"219","author":"Vergote","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"26","key":"10.1016\/j.ygyno.2025.11.022_bb0065","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO-25-00225","article-title":"Primary analysis of EPIK-O\/ENGOT-ov61: alpelisib plus olaparib versus chemotherapy in platinum-resistant or platinum-refractory high-grade serous ovarian cancer without BRCA mutation","volume":"43","author":"Konstantinopoulos","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.11.022_bb0070","series-title":"Abraxane [Product Monograph]","year":"2018"},{"key":"10.1016\/j.ygyno.2025.11.022_bb0075","series-title":"Abraxane [Package Insert]","year":"2020"},{"key":"10.1016\/j.ygyno.2025.11.022_bb0080","series-title":"Abraxane [Summary of Product Characteristics]","year":"2025"},{"issue":"31","key":"10.1016\/j.ygyno.2025.11.022_bb0085","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2025.11.022_bb0090","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2217\/cer-2019-0077","article-title":"Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer","volume":"8","author":"Luhn","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.ygyno.2025.11.022_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CMAR.S150960","article-title":"Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis","volume":"10","author":"Mahtani","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.11.022_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","article-title":"A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"122","author":"Coleman","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2025.11.022_bb0105","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.22.02624","article-title":"Relacorilant+ nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase II study","volume":"41","author":"Colombo","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10496","key":"10.1016\/j.ygyno.2025.11.022_bb0110","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ygyno.2025.11.022_bb0115","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.2217\/fon-2021-0573","article-title":"Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1\/L1 inhibitor therapy","volume":"17","author":"Hepp","year":"2021","journal-title":"Future Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.11.022_bb0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2018.7102","article-title":"Comparative effectiveness of carboplatin\/pemetrexed with versus without bevacizumab for advanced nonsquamous non\u2013small cell lung cancer","volume":"17","author":"Bagley","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"16","key":"10.1016\/j.ygyno.2025.11.022_bb0125","first-page":"20037143","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","volume":"03","author":"Ma","year":"2020","journal-title":"MedRxiv"},{"issue":"6 suppl 1","key":"10.1016\/j.ygyno.2025.11.022_bb0130","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/j.jval.2025.04.1177","article-title":"MSR24 leveraging machine learning to assess the association of rash and survival in patients with advanced NSCLC","volume":"28","author":"Yuan","year":"2025","journal-title":"Value Health"},{"issue":"28","key":"10.1016\/j.ygyno.2025.11.022_bb0135","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.022_bb0140","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1001\/jamaoncol.2020.3927","article-title":"Efficacy and safety of nab-paclitaxel vs paclitaxel on survival in patients with platinum-refractory metastatic urothelial cancer: the Canadian Cancer trials group BL.12 randomized clinical trial","volume":"6","author":"Sridhar","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2025.11.022_bb0145","series-title":"Presented at: The 15th Meeting of the International Charit\u00e9 Mayo Conference","article-title":"Evaluating nab-paclitaxel vs. paclitaxel in the treatment of recurrent platinum resistant ovarian cancer: Findings from a systematic literature review and interdisciplinary consensus","author":"Grabowski","year":"2025"},{"issue":"8","key":"10.1016\/j.ygyno.2025.11.022_bb0150","first-page":"1","article-title":"Recent advances in paclitaxel drug delivery: challenges, innovations, and future directions","volume":"8","author":"Ejeta","year":"2024","journal-title":"J. Angiother."},{"key":"10.1016\/j.ygyno.2025.11.022_bb0155","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.2147\/DDDT.S88023","article-title":"Albumin-bound paclitaxel in solid tumors: clinical development and future directions","volume":"9","author":"Kundranda","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.ygyno.2025.11.022_bb0160","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4103\/CRST.CRST_8_20","article-title":"Paclitaxel hypersensitivity","volume":"3","author":"Pavan Kumar","year":"2020","journal-title":"Cancer Res. Stat. Treat."},{"key":"10.1016\/j.ygyno.2025.11.022_bb0165","doi-asserted-by":"crossref","first-page":"1551111","DOI":"10.3389\/fphar.2025.1551111","article-title":"Rethinking corticosteroids use in oncology","volume":"16","author":"Martinez","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.11.022_bb0170","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-020-04140-x","article-title":"Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer","volume":"86","author":"Tsushima","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.022_bb0175","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2\/HER2-negative breast cancer \u2013 the evaluating treatment with neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial","volume":"4","author":"Gianni","year":"2018","journal-title":"JAMA Oncol."},{"issue":"17 suppl","key":"10.1016\/j.ygyno.2025.11.022_bb0180","article-title":"ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)","volume":"43","author":"Olawaiye","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2025.11.022_bb0185","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.39788","article-title":"Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer","volume":"5","author":"Mo","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.ygyno.2025.11.022_bb0190","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12282-024-01551-z","article-title":"A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer","volume":"31","author":"Kida","year":"2024","journal-title":"Breast Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2025.11.022_bb0195","article-title":"Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer","volume":"7","author":"Patel","year":"2022","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825011175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825011175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T08:10:41Z","timestamp":1766131841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825011175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S0090825825011175"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}